WebSite Macau: Neoral

Neoral is a brand name of cyclosporine, approved by the FDA in the following formulation(s):

NEORAL (cyclosporine - capsule; oral)

Manufacturer: NOVARTIS

Approval date: July 14, 1995

Strength(s): 100MG ^[RLD]^[AB1], 25MG ^[AB1]

NEORAL (cyclosporine - solution; oral)

Manufacturer: NOVARTIS

Approval date: July 14, 1995

Strength(s): 100MG/ML ^[RLD]^[AB1]

Has a generic version of Neoral been approved?

A generic version of Neoral has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Neoral and have been approved by the FDA:

cyclosporine capsule; oral

Manufacturer: IVAX SUB TEVA PHARMS

Approval date: March 29, 2005

Strength(s): 100MG ^[AB1], 25MG ^[AB1]

Manufacturer: PLIVA

Approval date: December 20, 2000

Strength(s): 100MG ^[AB1], 25MG ^[AB1]

Manufacturer: SANDOZ

Approval date: January 13, 2000

Strength(s): 100MG ^[AB1], 25MG ^[AB1]

cyclosporine solution; oral

Manufacturer: ABBOTT

Approval date: March 3, 2000

Strength(s): 100MG/ML ^[AB1]

Manufacturer: IVAX SUB TEVA PHARMS

Approval date: March 25, 2005

Strength(s): 100MG/ML ^[AB1]

Manufacturer: NOVEX

Approval date: January 5, 2005

Strength(s): 100MG/ML ^[AB1]

Manufacturer: WATSON LABS

Approval date: December 18, 2001

Strength(s): 100MG/ML ^[AB1]

GENGRAF (cyclosporine capsule; oral)

Manufacturer: ABBOTT

Approval date: May 12, 2000

Strength(s): 100MG ^[AB1], 25MG ^[AB1]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Neoral. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmaceutical compositions comprising cyclosporins
Patent 5,342,625
Issued: August 30, 1994
Inventor(s): Hauer; Birgit & Meinzer; Armin & Posanski; Ulrich & Richter; Friedrich
Assignee(s): Sandoz Ltd.
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.
Patent expiration dates:
- August 30, 2011
  ✓
  Drug product

Pharmaceutical compositions comprising cyclosporins
Patent 5,741,512
Issued: April 21, 1998
Inventor(s): Hauer; Birgit & Meinzer; Armin & Posanski; Ulrich & Richter; Friedrich
Assignee(s): Novartis Corporation
Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or ›Nva!.sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.
Patent expiration dates:
- August 30, 2011
  ✓
  Patent use: PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS
  ✓
  Drug product

Soft gelatin capsule manufacture
Patent 5,985,321
Issued: November 16, 1999
Inventor(s): Brox; Werner & Meinzer; Armin & Zande; Horst
Assignee(s): Novartis AG
R.P. Scherer GmbH
Soft gelatin capsules having a capsule shell comprising gelatin, plasticizers and, if desired or required, further auxiliary agents, and a capsule filling containing a solvent including a migrateable solvent such as 1,2-propyleneglycol as a solvent in the capsule filling and in the capsule shell. The manufacture of said capsules is improved, if in the process for making the soft gelatin capsules the gelatin bands are cooled with a liquid, and preferably with water.
Patent expiration dates:
- September 26, 2014
  ✓
  Drug product

Pharmaceutical composition
Patent 6,258,808
Issued: July 10, 2001
Inventor(s): Hauer; Birgit & Meinzer; Armin & Posanski; Ulrich & Vonderscher; Jacky
Assignee(s): Novartis AG
Pharmaceutical compositions comprising a cyclosporin in a novel galenic formulations for oral administration. The compositions typically comprise a cyclosporin, 1,2-propylene glycol, a mixed mono-,di- and tri-glyceride and a hydrophilic surfactant. Further a refined glycerol-transesterified corn oil is provided representing a mixed mono-, di- and tri-glyceride suitable for the novel formulation. Dosage forms include in particular oral dosage forms.
Patent expiration dates:
- June 25, 2012
  ✓
  Drug product

Pharmaceutical compositions containing cyclosporin as the active agent
Patent 6,262,022
Issued: July 17, 2001
Inventor(s): Hauer; Birgit & Meinzer; Armin & Posanski; Ulrich & Vonderscher; Jacky
Assignee(s): Novartis AG
Pharmaceutical compositions comprising a cyclosporin in a novel galenic formulations for oral administration. The compositions typically comprise a cyclosporin, 1,2-propylene glycol, a mixed mono-, di- and tri-glyceride and a hydrophilic surfactant. Further a refined glycerol-transesterified corn oil is provided representing a mixed mono-, di- and tri-glyceride suitable for the novel formulation. Dosage forms include in particular oral dosage forms.
Patent expiration dates:
- June 25, 2012
  ✓
  Drug product

WebSite Macau

Sunday, October 16, 2016

Neoral